Some compounding pharmacies are sidestepping the FDA's ban on copying approved GLP-1s by adding a vitamin or supplement to their formulations, according ...

Demand for compounded GLP-1 drugs persists despite shortage resolutions ...

Patricia Louis is a content editor and social media strategist with a strong background in journalism, public relations and business. As the organic social media editor, she oversees and develops ...

Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?

CVS Health will restore Eli Lilly’s weight-loss injection Zepbound to its list of covered drugs and also add the drugmaker’s newly approved obesity pill, Foundayo, it said today. CVS Caremark, one of ...

CVS Caremark has expanded coverage options for GLP-1 weight management medications, including the return of Zepbound as a preferred formulary option — reversing a decision that drew significant ...

More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for ...

Meaghan is an editor and writer who also has experience practicing holistic medicine as an acupuncturist and herbalist. She's passionate about helping individuals live full, healthy and happy lives at ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market. New York-based Regeneron made a ...

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device. Lilly says the new pen expands patient choice, ...

Eli Lilly LLY-2.33%decrease; down pointing triangle received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery option ...